VIR-5500

Multispecific antibody

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Prostate Cancer
NCT05997615 · Astellas Pharma Global Development, Inc.
2023-08-10 – 2030-06-30 · Hormone-refractory Prostate Cancer
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Prostate Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
VIR-5500: this drugPhase 1Multispecific antibodyPSMA x CD3not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
225Ac-PSMA-617Phase 3Radioligand Therapy (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)not yet gradedNo reviewed efficacy summary in this indication
JNJ-101556143Phase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
JNJ-87189401Phase 3Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RezvilutamidePhase 3Small moleculeAndrogen receptornot yet gradedNo reviewed efficacy summary in this indication
RinzimetostatPhase 3Small moleculeEED (PRC2)not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
Abiraterone DecanoatePhase 2Small moleculeCYP17 lyasenot yet gradedNo reviewed efficacy summary in this indication
HRS-5041Phase 2Small moleculeAndrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
MRT-2359Phase 2Small moleculeGSPT1not yet gradedNo reviewed efficacy summary in this indication
AMO959Phase 1/2Small moleculeDNA-PKnot yet gradedNo reviewed efficacy summary in this indication
AZD0516Phase 1/2Antibody–drug conjugateSTEAP2not yet gradedNo reviewed efficacy summary in this indication
AZD0754Phase 1/2Cell therapySTEAP2not yet gradedNo reviewed efficacy summary in this indication
AZD6621Phase 1/2Multispecific antibodySTEAP2 x CD3not yet gradedNo reviewed efficacy summary in this indication
HRS-1738Phase 1/2UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
NezastomigPhase 1/2Multispecific antibodyPSMA x CD28not yet gradedNo reviewed efficacy summary in this indication
OlsutamigPhase 1/2Multispecific antibodyPSMA x CD3not yet gradedNo reviewed efficacy summary in this indication
REGN15505Phase 1/2Multispecific antibodyPSMA x 4-1BBnot yet gradedNo reviewed efficacy summary in this indication
SHR-4394Phase 1/2Antibody–drug conjugatePSMAnot yet gradedNo reviewed efficacy summary in this indication
AZD2284Phase 1Radioconjugate (actinium-225)STEAP2not yet gradedNo reviewed efficacy summary in this indication
BMS-986460Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
INR731Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
JANX007Phase 1Multispecific antibodyPSMA x CD3not yet gradedNo reviewed efficacy summary in this indication
JNJ-95298177Phase 1Antibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
JNJ-98768111Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK5471713
—(overall)
UndisclosedAndrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
RG6537
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-7525
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow VIR-5500 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 1Prostate CancerRecruiting
Est. primary completion 2027-09-30 · NCT05997615 · CT.gov ↗
What to watch

See the full readout calendar ↗